KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

Author's Avatar
Jun 02, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Hamburg, Germany and virtually, from June 9-11. The presentations are: